
Drugs IPOs Depend o...


| PDFS | Sector Avg. | S&P 500 |
|---|---|---|
| 14.20 | 14.20 | 17.70 |
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| 14.06 | 106.70 | 263.40 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | 34.20 | 0.85 | 0.22 |
| Net Income | 1879.30 | -3.13 | 0.00 |
| EPS | 1685.70 | -2.97 | 0.00 |
| EBITDA | 21.97M |
| REVENUE | 89.54M |
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $0.14 | $0.17 | $0.65 | $0.94 |
| Number of Analysts | 1 | 1 | 1 | 1 |
| High Estimate | $0.14 | $0.17 | $0.65 | $0.94 |
| Low Estimate | $0.14 | $0.17 | $0.65 | $0.94 |
| Prior Year | $0.17 | $0.17 | $0.66 | $0.65 |
| Growth Rate (Year over Year) | -17.65% | 0.00% | -1.52% | 44.62% |